Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company focused on cancer treatment and prevention, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

Key points:

• Anixa's presentation will be available on-demand to registered attendees starting September 9, 2024, at 7:00 AM Eastern Time
• A webcast of the presentation can be accessed via a provided link and on Anixa's investor relations website
• Management will participate in one-on-one meetings with investors throughout the conference

Investors interested in scheduling a meeting with Anixa's management can contact anix@crescendo-ir.com.

SAN JOSE, Calif., Aug. 26, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11, 2024 at the Lotte New York Palace Hotel in New York City.

Anixa's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024, at 7:00 AM Eastern Time. A webcast of the Company's presentation can also be accessed at https://journey.ct.events/view/22198185-e09f-404c-a725-bf53bce656a8 and on the investor relations section of Company's website at https://ir.anixa.com/events.

Management will be participating in one-on-one meetings with investors throughout the conference in New York City. To request a meeting, please contact anix@crescendo-ir.com.

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302227713.html

SOURCE Anixa Biosciences, Inc.

FAQ

When is Anixa Biosciences (ANIX) presenting at the H.C. Wainwright Global Investment Conference?

Anixa Biosciences' presentation will be available on-demand to registered attendees starting September 9, 2024, at 7:00 AM Eastern Time.

Where can investors access Anixa Biosciences' (ANIX) presentation from the H.C. Wainwright conference?

Investors can access the webcast of Anixa's presentation via a provided link and on the investor relations section of the company's website at https://ir.anixa.com/events.

How can investors schedule a meeting with Anixa Biosciences (ANIX) management at the H.C. Wainwright conference?

Investors interested in scheduling a one-on-one meeting with Anixa Biosciences' management during the conference can contact anix@crescendo-ir.com.

What is the focus of Anixa Biosciences (ANIX) as a biotechnology company?

Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.